Inhibikase Therapeutics Files Definitive Proxy Statement

TL;DR

IKT proxy filing out for Aug 5 meeting - shareholders vote soon.

AI Summary

Inhibikase Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on June 20, 2024, for its annual meeting scheduled for August 5, 2024. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for the upcoming annual meeting, including any proposals or director elections, allowing them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders about an upcoming meeting, rather than announcing significant new business developments or financial results.

Key Players & Entities

• Inhibikase Therapeutics, Inc. (company) — Registrant
• August 5, 2024 (date) — Annual Meeting Date
• June 20, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — 5 shares of our common stock, par value $0.001 per share (“ Common Stock &#x201
• $10,500 — reed to pay Kingsdale Advisors a fee of $10,500 plus reimburse them for certain out-of-

Filing Documents

• ikt-proxy_special-2024_d.htm (DEF 14A) — 192KB
• img232124869_0.jpg (GRAPHIC) — 79KB
• img232124869_1.jpg (GRAPHIC) — 403KB
• 0000950170-24-075675.txt ( ) — 853KB

From the Filing

DEF 14A 1 ikt-proxy_special-2024_d.htm DEF 14A DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to 240.14a-12 Inhibikase Therapeutics, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. ☐ Fee paid previously with preliminary materials. ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. INHIBIKASE THERAPEUTICS, INC. 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA, GEORGIA 30339 (678) 392-3419 June 20, 2024 Dear Fellow Stockholder: You are cordially invited to attend a Special Meeting of Stockholders (the “ Special Meeting ”) of Inhibikase Therapeutics, Inc. (“ Inhibikase ,” the “ Company ,” “ we ” or “ us ”) to be held at 4:00 p.m., Eastern Time , on Monday, August 5, 2024 . We are very pleased that the Special Meeting will be a completely virtual meeting of stockholders, which will be conducted via live webcast. The Special Meeting will be held in a virtual format only, via the Internet, with no physical in-person meeting. You will be able to attend the Special Meeting online and submit your questions during the meeting by visiting https://web.lumiconnect.com/235841686, password inhibikase2024 . You will also be able to vote your shares electronically at the Special Meeting. We are pleased to use the latest technology to increase access, to improve communication and to obtain cost savings for our stockholders and the Company. Use of a virtual meeting will enable increased stockholder attendance and participation as stockholders can participate from any location. At the meeting, you will be asked to approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of certain common stock purchase warrants in connection with a private placement and in connection with a warrant inducement. Detailed information with respect to this matter is set forth in the accompanying Proxy Statement, which we encourage you to carefully read in its entirety. We look forward to greeting personally those stockholders who are able to attend the meeting online. However, whether or not you plan to join us at the meeting, it is important that your shares be represented. Stockholders of record at the close of business on June 10, 2024 are entitled to notice of and to vote at the meeting. Such stockholders are urged to promptly submit the enclosed proxy card, even if their shares were sold after the record date. You may vote over the Internet, as well as by telephone or by mail pursuant to instructions provided on the proxy card. Please review the instructions for each of your voting options described in the Proxy Statement. Thank you for your ongoing support of Inhibikase. Very truly yours, /s/ Milton H. Werner Milton H. Werner, Ph.D. President and Chief Executive Officer INHIBIKASE THERAPEUTICS, INC. NOTICE OF SPECIAL MEETING OF STOCKHOLDERS Notice is hereby given that a Special Meeting of Stockholders (the “ Special Meeting ”) of Inhibikase Therapeutics, Inc. (“ Inhibikase ” or the “ Company ”), will be held virtually at 4:00 p.m., Eastern Time , on Monday, August 5, 2024 , for the following purposes: • to approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of certain common stock purchase warrants in connection with a private placement and in connection with a warrant inducement (the “ Warrant Issuance Proposal ”); and • to consider and act upon such other matters as may properly come before the meeting or any postponement or adjournment of the meeting. These matters are more fully described in the accompanying Proxy Statement. Only stockholders of record at the close of business on June 10, 2024 are entitled to notice of and to vote at the Special Meeting and any adjournment or postponement thereof. The Special Meeting will be held in a virtual format only, via the Internet, with no physical in-person meeting. Stockholders will have the ability to attend, vote and submit questions before and during the virtual meeting from any location via the Internet at https://web.lumiconnect.com/235841686, password inhibikase2024 . A complete list of these stockholders will be available in electronic form at the Special Meeting and will be a

View Full Filing

View this DEF 14A filing on SEC EDGAR